Life Edit Therapeutics
507 Airport Blvd. Suite 101
About Life Edit Therapeutics
Life Edit Therapeutics, an ElevateBio company, is a next-generation genome editing company that has built a highly innovative platform with one of the world’s largest and most diverse collections of novel RNA-guided nucleases (RGNs) and base editors. The platform allows Life Edit to target any genomic sequence and develop novel human therapeutics for the most challenging genetic diseases by enabling ex vivo engineering for cell therapies and regenerative medicines and in vivo delivery of gene therapies. In addition to developing its own pipeline of cell and gene therapies, Life Edit Therapeutics will continue to strengthen its platform of genome-editing enzymes, provide gene-editing expertise to strategic partners, and form other third-party partnerships to discover and develop new therapies.
3 articles about Life Edit Therapeutics
The Massachusetts-based company has claimed the year’s largest fundraise so far and secured a powerhouse R&D partner in Novo Nordisk to develop gene editing medicines.
Life Edit Therapeutics to Present Data Demonstrating Therapeutic Potential of its Novel Gene Editing Platform
-Life Edit Therapeutics Inc. today announced the presentation of the first preclinical data from the company's Huntington's disease program across three presentations at CHDI’s 18th Annual Huntington’s Disease Therapeutics Conference taking place April 24-27, 2023, in Dubrovnik, Croatia.
Moderna And Life Edit Therapeutics Enter Strategic Collaboration to Accelerate the Development of Novel In Vivo Gene Editing Therapies
Collaboration to combine Moderna's mRNA platform with Life Edit's proprietary gene editing technologies, including base editing capabilities Multi-target collaboration to advance potentially life-transformative or curative therapies for some of the most challenging genetic diseases .